Experience with regorafenib in the treatment of hepatocellular carcinoma

Regorafenib is a diphenylurea oral multikinase inhibitor, structurally comparable to sorafenib, which targets a variety of kinases implicated in angiogenic and tumor growth-promoting pathways. Regorafenib was the first agent to positively show significant survival advantage as a second-line therapy...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Therap Adv Gastroenterol
Main Authors: Granito, Alessandro, Forgione, Antonella, Marinelli, Sara, Renzulli, Matteo, Ielasi, Luca, Sansone, Vito, Benevento, Francesca, Piscaglia, Fabio, Tovoli, Francesco
Format: Artigo
Sprog:Inglês
Udgivet: SAGE Publications 2021
Fag:
Review
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC8165525/
https://ncbi.nlm.nih.gov/pubmed/34104211
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17562848211016959
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker